PTC Therapeutics, Inc. (PTCT) Guidance & Earnings Results
On 2026-07-30 PTC Therapeutics, Inc. raised guidance: "Total revenue guidance raised to $1.18-$1.28B; product revenue guidance raised to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PTCTPTC Therapeutics, Inc.Follow PTCT — free
—
Price chart with a free account
- Market cap
- 5.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | Raised | Total revenue guidance raised to $1.18-$1.28B; product revenue guidance raised to $850-$950M · full year |
| 7 May 26 | Raised | Product revenue guidance raised to $750-850M; total revenue $1.08-1.18B. · full year |
| 19 Feb 26 | Raised | Full-year 2025 product and royalty revenue of $831M exceeded guidance · full year |
| 12 Jan 26 | Raised | FY2025 revenue ~$823M exceeded guidance; FY2026 product revenue guidance $700-800M (19-36% growth) |
| 4 Nov 25 | Reaffirmed | FY2025 revenue guidance narrowed to $750-800M · full year |
| 7 Aug 25 | Reaffirmed | FY2025 revenue $650-800M; GAAP R&D+SG&A $805-835M; non-GAAP R&D+SG&A $730-760M (excl. $75M stock-based comp) · full year |
PTC Therapeutics, Inc. — questions
- What guidance did PTC Therapeutics, Inc. give?
- On 2026-07-30: "Total revenue guidance raised to $1.18-$1.28B; product revenue guidance raised to $850-$950M"
- When does PTC Therapeutics, Inc. report earnings?
- PTC Therapeutics, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from PTC Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.